Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Acadia Pharmaceuticals reported strong financial results for the first quarter of 2024, with net product sales reaching $205.8 million, a 74% year-over-year revenue growth. The increase was primarily driven by the addition of DAYBUE for Rett syndrome treatment and growth in NUPLAZID market share for Parkinson's disease psychosis. The company is focusing on expanding DAYBUE globally, advancing late-stage trials, and supporting its pipeline and business development opportunities. Acadia also presented positive clinical trial results and appointed a new executive to lead Research and Development.
Acadia Pharmaceuticals announced the winners of the first Rett Sibling Scholarship, awarding 10 academic scholarships to siblings of Rett syndrome patients. Each recipient will receive $5,000 for higher education. The program aims to support siblings' academic goals and recognize their contributions. Recipients from various states plan to study psychology, finance, and medicine. The scholarship is independently administered by ISTS. Acadia's commitment to the Rett syndrome community is highlighted through this initiative.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.